Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer

Chinese Academy of Medical Sciences28 enrolled

Overview

For patients resistant to enthrycycline and taxanes, there is no standard regimen. Pemetrexed alone had certain efficacy in treatment of advance breast cancer. Platin was also a effective drug for advanced breast cancer. The combination of these two drug may have a synergy with each other in treatment of advanced breast cancer.

combination of pemetrexed and cisplatin to treat advanced breast cancer. Previous regimen no more than 3 which including enthrycycline and taxanes(paclitaxel and/or docetaxel)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Locally Advanced Malignant Neoplasm

Interventions

pemetrexed plus cisplatinDRUG

pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18-70 years old * Resistant to enthracycle and taxanes * Has measurable disease Exclusion Criteria: * Has more than 3 previous chemotherapy regimens

Locations (1)

Cancer Institute & Hospital. Chinese Academy of Medical Sciences

Beijing, China

Outcomes

Primary Outcomes

PFS (progression free survival)

Time frame: 2 Years

Secondary Outcomes

Safety

Assessing for Hematology and Non-hematology toxicities, including all SAEs.

Time frame: 2 years

Response Rate

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.